Trientine tetrahydrochloride (Cuvrior) is approved to treat adults with stable Wilson’s disease who are decoppered and tolerant to penicillamine.
FDA Approvals
FDA Approvals
FDA Approves New Drug for Wilson’s Disease
Trientine tetrahydrochloride (Cuvrior) is approved to treat adults with stable Wilson's disease who are decoppered and tolerant to penicillamine.
FDA Approvals
FDA Approvals